Evotec SE (EVO)
| Market Cap | 3.67B |
| Revenue (ttm) | 799.41M |
| Net Income (ttm) | -186.87M |
| Shares Out | 354.37M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | 89.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,011 |
| Open | 10.42 |
| Previous Close | 10.21 |
| Day's Range | 10.22 - 10.49 |
| 52-Week Range | 7.80 - 13.49 |
| Beta | 0.98 |
| Analysts | Buy |
| Price Target | 14.33 (+38.45%) |
| Earnings Date | Nov 8, 2023 |
About EVO
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol ... [Read more]
Full Company ProfileAnalyst Forecast
According to 5 analysts, the average rating for EVO stock is "Buy." The 12-month stock price forecast is $14.33, which is an increase of 38.45% from the latest price.
News
Evotec SE Reports Results for the First Half-year 2023 and Provides Corporate Updates
NEW AND EXTENDED ALLIANCES UNDERLINE PIPELINE VALUE POTENTIAL NEW GUIDANCE FOR FULL-YEAR 2023 CONFIRMED HAMBURG, GERMANY / ACCESSWIRE / August 29, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/...
Evotec SE Reports First Half-Year 2023 Results on 29 August 2023
HAMBURG, GERMANY / ACCESSWIRE / August 22, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first half-year of 2...
Evotec Provides Update on Financial Impact of Cyber-Attack
HAMBURG, GERMANY / ACCESSWIRE / July 27, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it is adjusting its guidance for the fiscal y...
Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership
EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATION SELECTED PROGRAMMES FURTHER STRENGTHEN THE PROGRAMME PIPE...
Just - Evotec Biologics Awarded Second Contract from U.S. Department of Defense Under Accelerated Antibodies Program
JUST - EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS MABS TARGETING ORTHOPOXVIRUSES PROJECT INCLUDES EXISTING ANTIBODY DEVELOPMENT, ANTIBODY DISCOVE...
Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme
PHASE I CLINICAL TRIAL INITIATED TO EVALUATE SEMA3A MAB AS POTENTIAL TREATMENT FOR ALPORT SYNDROME FIRST DOSING OF FIRST STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 2 M TO EVOTEC HAMBURG, GERMAN...
Evotec SE Annual General Meeting 2023 Approves All Proposed Agenda Items
ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY REPORT OF FIRST HALF-YEAR 2023 RESULTS ON 29 AUGUST 2023 HAMBURG, GERMANY / ACCESSWIRE / June 20, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MD...
Evotec Presents Sustainability Strategy
TOGETHER FOR A SUSTAINABLE AND EFFICIENT SHARED R&D ECONOMY PRECISION MEDICINES AND BETTER ACCESS TO BIOTHERAPEUTICS ESG PERFORMANCE REPORT HIGHLIGHTS SUSTAINABILITY AS A COMPETITIVE ADVANTAGE IN CHAL...
Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics
$ 1.7 M-GRANT FROM OPEN PHILANTHROPY WILL SUPPORT DEVELOPMENT OF SMALL MOLECULE ANTIVIRALS THAT TARGET VIRAL RNA IN HENIPAVIRUSES EVOTEC LEVERAGES ITS PROPRIETARY SMALL MOLECULE RNA TARGETING PLATFORM...
Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
PUBLICATION OF ANNUAL REPORT 2022: "AHEAD OF THE CURVE" QUALITATIVE QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2023 GUIDANCE FOR FY2023 AND MID-TERM GUIDANCE FOR 2025 UNCHANGED HAMBURG, GERMANY / AC...
Just - Evotec Biologics Enters Strategic Biosimilars Partnership with Sandoz
HHAMBURG, GERMANY / ACCESSWIRE / May 9, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that Evotec's Seattle-based subsidiary...
Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
JUST - EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULES JUST - EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS D...
Evotec SE Provides Update on Cyber Attack
Business continuity upheld at all global sites after cyber attack Forensic examination ongoing with external experts HAMBURG, GERMANY / ACCESSWIRE / April 10, 2023 / Evotec SE (FFSE:EVT, MDAX/TecDAX, ...
Cyber Attack on Evotec
HAMBURG, GERMANY / ACCESSWIRE / April 7, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN:DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that on 06 April, 2023 a cyber attack occ...
Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
8-YEAR EXTENSION AND EXPANSION OF ONGOING COLLABORATION TO DEVELOP A BROADENED PROGRAMME PIPELINE IN NEURODEGENERATIVE DISEASES PARTNERSHIP LEVERAGES EVOTEC'S PRECISION MEDICINE PLATFORMS FINANICAL TE...
Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year
22% INCREASE IN GROUP REVENUES; EBITDA EXCLUDING M&A AT € 104.1 M POSITIVE MOMENTUM AND OUTLOOK FOR 2023 DATA-DRIVEN PLATFORMS RESULTING IN LARGEST ALLIANCE IN TARGETED PROTEIN DEGRADATION IN THE INDU...
Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis
GRANT FROM THE BILL & MELINDA GATES FOUNDATION SUPPORTS EVOTEC'S EFFORTS TO DISCOVER AND DEVELOP DRUG CANDIDATES FOR A UNIVERSAL, SHORTER, SAFER AND SIMPLER TUBERCULOSIS DRUG REGIMEN AS ONE OF ITS PRO...
Evotec SE to Announce Preliminary Financial Results for Fiscal Year 2022 on 28 March 2023
HAMBURG, GERMANY / ACCESSWIRE / March 21, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN: DE0005664809)(NASDAQ:EVO) will announce its preliminary financial results for 2022 on Tuesd...
Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
KEY SCIENTIFIC ACHIEVEMENTS DRIVE THE EXPANSION OF THE PIPELINE OF MOLECULAR GLUE DEGRADERS PERFORMANCE-BASED AND PROGRAMME-BASED PAYMENTS OF IN TOTAL US$ 75 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE ...
Evotec Receives € 150 m Loan from European Investment Bank
FINANCING FOR 3 CORE PILLARS: R&D ACTIVITIES, EQUITY INVESTMENTS AND CONSTRUCTION OF MANUFACTURING FACILITY DEDICATED TO BIOLOGICS, J.POD ® TOULOUSE, FRANCE (EU) FOLLOW-ON TO THE EXISTING € 75 M LOAN ...
Evotec and Related Sciences Expand Integrated Drug Discovery and Development Partnership
EVOTEC AND RELATED SCIENCES COLLABORATE BY COMBINING COMPLEMENTARY CAPABILITIES TO ADVANCE PORTFOLIOS OF TRANSFORMATIONAL NEW MEDICINES THE PARTNERSHIP OVERSEES A GROWING PORTFOLIO OF MORE THAN 15 MUL...
Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
HAMBURG, GERMANY / ACCESSWIRE / February 7, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company's Supervisory Board has appoi...
Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies
STRATEGIC PARTNERSHIP LEVERAGES EVOTEC'S EXPERTISE & INTEGRATED PLATFORM FOR DISCOVERY AND DEVELOPMENT HAMBURG, GERMANY / ACCESSWIRE / January 26, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/...
Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
THE COLLABORATION ADDS TWO DRUG DISCOVERY PROJECTS TO THE PORTFOLIO AND DESIGNATES A TARGET-BASED PROGRAMME FOR DEVELOPMENT EVOTEC RECEIVES PAYMENTS IN TOTAL OF US$ 26 M FROM BRISTOL MYERS SQUIBB HAMB...
Evotec SE to Announce Results for the First Nine Months 2022 on 09 November 2022
HAMBURG, GERMANY / ACCESSWIRE / November 3, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first nine months 2...